Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

BACKGROUND: Patients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ESMO Open
Auteurs principaux: Fujiwara, Yutaka, Kuchiba, Aya, Koyama, Takafumi, Machida, Ryunosuke, Shimomura, Akihiko, Kitano, Shigehisa, Shimizu, Toshio, Yamamoto, Noboru
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2020
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174012/
https://ncbi.nlm.nih.gov/pubmed/32276948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000653
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires